Oruka Therapeutics (NASDAQ:ORKA) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report issued on Monday morning,Benzinga reports. They currently have a $45.00 price target on the stock. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($2.24) EPS, Q3 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.98) EPS.

Several other analysts have also recently weighed in on ORKA. TD Cowen assumed coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating on the stock. Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Lifesci Capital began coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective for the company. Stifel Nicolaus started coverage on Oruka Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $49.00 target price on the stock. Finally, Leerink Partners assumed coverage on shares of Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 target price for the company. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Oruka Therapeutics has a consensus rating of “Buy” and a consensus price target of $43.17.

Oruka Therapeutics Trading Up 8.4 %

NASDAQ:ORKA opened at $20.26 on Monday. Oruka Therapeutics has a one year low of $18.20 and a one year high of $53.88. The firm has a market cap of $709.08 million, a P/E ratio of -3.24 and a beta of 0.87. The stock’s 50 day simple moving average is $25.76.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new position in Oruka Therapeutics in the third quarter valued at approximately $343,000. The Manufacturers Life Insurance Company bought a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at $1,037,000. Wellington Management Group LLP acquired a new position in shares of Oruka Therapeutics during the 3rd quarter valued at $2,013,000. Janus Henderson Group PLC bought a new position in Oruka Therapeutics during the third quarter worth $5,840,000. Finally, Redmile Group LLC acquired a new stake in Oruka Therapeutics in the third quarter worth $10,091,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.